Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIMUS 001: An Adaptive Phase II Study of FOLFOX-A (FOLFOX and Nab-paclitaxel) Versus AG (Nab-paclitaxel and Gemcitabine) in Patients With Metastatic Pancreatic Cancer, With Integrated Biomarker Evaluation

NCT04151277 is registered in ClinicalTrials.gov with Judith Dixon-Hughes as lead sponsor.

NCT NCT04151277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04151277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIMUS 001: An Adaptive Phase II Study of FOLFOX-A (FOLFOX and Nab-paclitaxel) Versus AG (Nab-paclitaxel and Gemcitabine) in Patients With Metastatic Pancreatic Cancer, With Integrated Biomarker Evaluation
Lead sponsor
Judith Dixon-Hughes
Phase
Phase 2
Overall status
Unknown status
Start date
November 28, 2017
Completion date
January 31, 2026
Enrollment
500 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms pancreatic